- In January 2025, Vanda Pharmaceuticals launched a direct-to-patient education portal to improve awareness and facilitate online consultations for Non-24.
- In February 2025, Takeda announced clinical trial results for a novel melatonin receptor agonist showing improved sleep parameters in Non-24 patients.
- In March 2025, Glenmark Pharmaceuticals entered into a licensing agreement to distribute Non-24 therapies in Latin America.
- In April 2025, Apotex initiated a clinical trial for a generic formulation of tasimelteon to expand access in emerging markets
